- Adagio Therapeutics Inc ADGI announced that the independent data monitoring committee (IDMC) has recommended expanding the ADG20 EVADE Phase 2/3 trial for COVID-19.
- The IDMC has supported the expansion of Phase 3 trial enrollment to include adolescents and pregnant or nursing women and decrease the protocol-specified, post-injection monitoring time.
- The IDMC’s assessments are based on their review of unblinded safety and tolerability data from 200 participants enrolled in the Phase 2 lead-in portion of the trial.
- ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
- Price Action: ADGI stock is up 0.47% at $47.13 during the market session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
